Devonian Health Group Inc.

Equities

GSD

CA2518341078

Pharmaceuticals

Market Closed - Toronto S.E. 03:01:37 2024-04-23 pm EDT 5-day change 1st Jan Change
0.22 CAD 0.00% Intraday chart for Devonian Health Group Inc. 0.00% +51.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7% MT
Devonian Health Group Inc. announced that it has received CAD 0.2238 million in funding CI
Devonian Health Group Inc. Appoints Kathryn J. Gregory to the Board CI
Devonian Announces $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
Devonian Health Group Inc. Announces CEO Changes CI
Devonian Health Group Inc. Announces Changes to its Board CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
Devonian Health Group Inc. Files Patent Cooperation Treaty Application for Thykamine?? in Wound Healing CI
Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding CI
Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding CI
Devonian Health Group Plans to Raise Up To $5 Million via Private Placement MT
Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding CI
Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update CI
Devonian Health Group Announces the Appointment of New Board Members CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023 CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023 CI
Devonian Health Group Inc. Announces Executive Appointments CI
Devonian Health Group Inc. Announces Executive Changes CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022 CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022 CI
Devonian Health Group Inc. Auditor Raises 'Going Concern' Doubt CI
Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases CI
Chart Devonian Health Group Inc.
More charts
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.
More about the company
  1. Stock Market
  2. Equities
  3. GSD Stock
  4. News Devonian Health Group Inc.
  5. Devonian Health Group Plans to Raise Up To $5 Million via Private Placement